StockMacro
Menu

Vertex Pharmaceuticals

$515.02 +18% in 6 monthsMarket cap $130.6B

VRTX on XNAS, Health Care, Vertex Pharmaceuticals Inc, job postings

Measures activity, not value. Not investment advice.

Revenue rose 10% to $13B and shares gained 22% in the past year.

  • GoodInstitutional holders rose to 1,772 from 1,717 last quarter

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Industry
Pharmaceutical preparations (Health Care)
Employees
6,400
Website
vrtx.com
Listed
Nasdaq, US
Last results
2 Nov 2026
Next results
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $3.4B, net income $653.6M.
Quarter to 31 Dec 2021: revenue $2.1B, net income $770.1MQuarter to 31 Dec 2021: revenue $2.1B, net income $770.1MQuarter to 31 Mar 2022: revenue $2.1B, net income $762.1MQuarter to 31 Mar 2022: revenue $2.1B, net income $762.1MQuarter to 30 Jun 2022: revenue $2.2B, net income $810.5MQuarter to 30 Jun 2022: revenue $2.2B, net income $810.5MQuarter to 30 Sep 2022: revenue $2.3B, net income $930.5MQuarter to 30 Sep 2022: revenue $2.3B, net income $930.5MQuarter to 31 Dec 2022: revenue $2.3B, net income $818.9MQuarter to 31 Dec 2022: revenue $2.3B, net income $818.9MQuarter to 31 Mar 2023: revenue $2.4B, net income $699.8MQuarter to 31 Mar 2023: revenue $2.4B, net income $699.8MQuarter to 30 Jun 2023: revenue $2.5B, net income $915.7MQuarter to 30 Jun 2023: revenue $2.5B, net income $915.7MQuarter to 30 Sep 2023: revenue $2.5B, net income $1.0BQuarter to 30 Sep 2023: revenue $2.5B, net income $1.0BQuarter to 31 Dec 2023: revenue $2.5B, net income $968.8MQuarter to 31 Dec 2023: revenue $2.5B, net income $968.8MQuarter to 31 Mar 2024: revenue $2.7B, net income $1.1BQuarter to 31 Mar 2024: revenue $2.7B, net income $1.1BQuarter to 30 Jun 2024: revenue $2.6B, net income -$3.6BQuarter to 30 Jun 2024: revenue $2.6B, net income -$3.6BQuarter to 30 Sep 2024: revenue $2.8B, net income $1.0BQuarter to 30 Sep 2024: revenue $2.8B, net income $1.0BQuarter to 31 Dec 2024: revenue $2.9B, net income $913.0MQuarter to 31 Dec 2024: revenue $2.9B, net income $913.0MQuarter to 31 Mar 2025: revenue $2.8B, net income $646.3MQuarter to 31 Mar 2025: revenue $2.8B, net income $646.3MQuarter to 30 Jun 2025: revenue $3.0B, net income $1.0BQuarter to 30 Jun 2025: revenue $3.0B, net income $1.0BQuarter to 30 Sep 2025: revenue $3.1B, net income $1.1BQuarter to 30 Sep 2025: revenue $3.1B, net income $1.1BQuarter to 31 Dec 2025: revenue $3.2B, net income $1.2BQuarter to 31 Dec 2025: revenue $3.2B, net income $1.2BQuarter to 31 Mar 2026: revenue $3.0B, net income $1.0BQuarter to 31 Mar 2026: revenue $3.0B, net income $1.0BQuarter to 30 Jun 2026: revenue $3.3B, net income $1.1BQuarter to 30 Jun 2026: revenue $3.3B, net income $1.1BQuarter to 30 Sep 2026: revenue $3.4B, net income $653.6MQuarter to 30 Sep 2026: revenue $3.4B, net income $653.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $3.6B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$3.4B$653.6M
30 Jun 2026$3.3B$1.1B
31 Mar 2026$3.0B$1.0B
31 Dec 2025$3.2B$1.2B
30 Sep 2025$3.1B$1.1B
30 Jun 2025$3.0B$1.0B
31 Mar 2025$2.8B$646.3M
31 Dec 2024$2.9B$913.0M
30 Sep 2024$2.8B$1.0B
30 Jun 2024$2.6B-$3.6B
31 Mar 2024$2.7B$1.1B
31 Dec 2023$2.5B$968.8M
30 Sep 2023$2.5B$1.0B
30 Jun 2023$2.5B$915.7M
31 Mar 2023$2.4B$699.8M
31 Dec 2022$2.3B$818.9M
30 Sep 2022$2.3B$930.5M
30 Jun 2022$2.2B$810.5M
31 Mar 2022$2.1B$762.1M
31 Dec 2021$2.1B$770.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $13.0B $11.7B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +10% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $4.0B $3.7B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $15.53 $14.21
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 85.5% 86.3% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 33.2% 34.1% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 30.7% 31.3% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 20.8% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $3.2B $3.3B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $6.3B $6.3B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $4.5B –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$1.8B (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.22 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $82.46
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 32.8 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 10.1 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 9.9 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 6.2 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Vertex PharmaceuticalsVRTX (this company) $130.6B32.810.1+10%30.7%
Bristol-Myers SquibbBMY $120.2B13.02.4+4.2%18.5%
PfizerPFE $156.2B38.72.5+1.3%6.3%
Abbott LaboratoriesABT $178.4B37.93.7+10%9.7%
Regeneron PharmaceuticalsREGN $95.2B19.85.6+19%28.5%
MerckMRK $329.7B1344.9+4.9%3.6%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$15.4M

bought $0, sold $15.4M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.2%

1,772 13F filers vs 1,717

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

94%

238.4M shares held by 13F filers (30 Sep 2026) of 253.5M outstanding (31 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.9%

4.8M shares sold short (30 Oct 2026) of 253.5M outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.4

4.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+13%

4.3M shares sold short in the report before, 4.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

48%

48% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 51%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

268

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+5.9%

198 vs 187 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+12%

$3.4B vs $3.1B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-4.4%

$97.3M vs $101.8M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$4.6M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

48

48 articles in the last 7 days; its usual week has 6.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

7.4×

48 articles in the last 7 days; its usual week has 6.5.

Price $515.02 on 20 Nov 2026, +22% over 12 months (12-month range $422.32 to $558.88)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $140.1M in the last 12 months (the 12 months before: -$47.1M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 197 published in the last 12 months, +4.8% on the 12 months before.
Revenue per quarter. Revenue $3.4B in the latest quarter, +12% on a year earlier.
Capital spending per quarter. Capital spending $97.3M in the latest quarter, -4.4% on a year earlier.
Institutional holders (13F filers). 1,772 13F filers reported holding it in the latest 13F quarter, +23% on a year earlier.
Lobbying spend. Lobbying spend: $4.6M published in the last 12 months, -4.4% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
20 Oct 20268-K and other filingsDirector or officer change
1 Sep 20268-K and other filingsDirector or officer change
1 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jul 2026Sharp changeLobbying on a new issue: lobbying on a new issue: DOC (2026-06-30)
13 May 20268-K and other filingsDirector or officer change
29 Apr 20268-K and other filingsDirector or officer change
29 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Apr 2026Lobbying filinglobbying engagement terminated (SALT POINT STRATEGIES)
20 Mar 2026Lobbying filingnew lobbying registration (ALSTON & BIRD LLP)
10 Mar 2026Lobbying filingnew lobbying registration (ALB SOLUTIONS)
17 Feb 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 149.4M vs usual 68.7M (2025-12-31); 1.6x the same period a year earlier
21 Jan 2026Sharp changeLobbying on a new issue: lobbying on a new issue: VET (2025-12-31)
7 Aug 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 145.7M vs usual 63.6M (2025-06-30); 2.1x the same period a year earlier
4 Aug 20258-K and other filingsDirector or officer change
4 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Apr 2025Sharp changeLobbying on a new issue: lobbying on a new issue: DEF, TRD (2025-03-31)
3 Apr 2025Lobbying filingnew lobbying registration (MCLARTY INBOUND LLC)
1 Apr 2025Sharp changeShort interest spike: short interest spike, 5.8M vs usual 4.2M (2025-03-14); 1.4x the same period a year earlier
24 Mar 2025Lobbying filingnew lobbying registration (MARSHALL & POPP, LLC)
24 Feb 2025Lobbying filingnew lobbying registration (SALT POINT STRATEGIES)
10 Feb 20258-K and other filingsDirector or officer change
10 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Feb 2025Sharp changeWikipedia attention spike: wikipedia attention spike, 9,043 vs usual 1,519.50 (2025-01-27..2025-02-02); 2.8x the same week a year earlier
9 Jan 2025Lobbying filingnew lobbying registration (HOLLAND & KNIGHT LLP)
19 Dec 2024Lobbying filingnew lobbying registration (CGCN GROUP, LLC)
22 Apr 2024Sharp changeLobbying on a new issue: lobbying on a new issue: HOM (2024-03-31)
5 Mar 2024Sharp changeShort interest spike: short interest spike, 4.1M vs usual 2.9M (2024-02-15); 1.5x the same period a year earlier
5 Dec 20238-K and other filingsDirector or officer change
5 Oct 20238-K and other filingsDirector or officer change
5 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Aug 2023Lobbying filingnew lobbying registration (AVENUE SOLUTIONS)
20 Jul 2023Lobbying filinglobbying engagement terminated (CAPITOL COUNSEL LLC)
14 Jul 2023Lobbying filinglobbying engagement terminated (WILLIAMS AND JENSEN, PLLC)
22 Jun 2023Lobbying filingnew lobbying registration (CROSSROADS STRATEGIES, LLC)
5 Jul 20228-K and other filingsA major agreement ended
15 Feb 2022Sharp changeQuarterly revenue change: quarterly revenue change, 2.1B vs usual 1.6B (2021-12-31); 1.3x the same period a year earlier
25 Jan 2022Sharp changeLobbying spend jump: lobbying spend jump, 630K vs usual 435K (2021-12-31); 1.1x the same period a year earlier
Insider net buying (open market)
Month from 1 Feb 2022: -$5.7M published
Month from 1 Mar 2022: -$3.9M published
Month from 1 Apr 2022: -$15.3M published
Month from 1 May 2022: -$565K published
Month from 1 Jun 2022: -$3.4M published
Month from 1 Jul 2022: -$42.3M published
Month from 1 Aug 2022: -$14.7M published
Month from 1 Oct 2022: -$730K published
Month from 1 Nov 2022: -$505K published
Month from 1 Jan 2023: -$9.0M published
Month from 1 Feb 2023: -$12.5M published
Month from 1 Mar 2023: -$6.5M published
Month from 1 Apr 2023: -$9.6M published
Month from 1 May 2023: -$8.6M published
Month from 1 Jun 2023: -$3.1M published
Month from 1 Jul 2023: -$6.8M published
Month from 1 Aug 2023: -$10.0M published
Month from 1 Sep 2023: -$4.0M published
Month from 1 Oct 2023: -$9.3M published
Month from 1 Nov 2023: -$11.5M published
Month from 1 Dec 2023: -$17.8M published
Month from 1 Jan 2024: -$4.0M published
Month from 1 Feb 2024: -$28.5M published
Month from 1 Apr 2024: -$101K published
Month from 1 May 2024: -$12.4M published
Month from 1 Jun 2024: -$11.2M published
Month from 1 Jul 2024: -$9.8M published
Month from 1 Aug 2024: -$12.1M published
Month from 1 Sep 2024: -$2.2M published
Month from 1 Oct 2024: -$461K published
Month from 1 Nov 2024: -$9.4M published
Month from 1 Feb 2025: -$6.7M published
Month from 1 Mar 2025: -$12.2M published
Month from 1 May 2025: -$224K published
Month from 1 Aug 2025: $5.7M published
Month from 1 Oct 2025: -$281K published
Month from 1 Nov 2025: -$33.4M published
Month from 1 Dec 2025: -$37.2M published
Month from 1 Jan 2026: -$6.5M published
Month from 1 Feb 2026: -$43.4M published
Month from 1 Mar 2026: -$25.1M published
Month from 1 Apr 2026: -$1.5M published
Month from 1 May 2026: -$4.4M published
Month from 1 Jun 2026: -$4.3M published
Month from 1 Jul 2026: -$2.3M published
Month from 1 Nov 2026: -$15.4M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 15 published
Quarter from 1 Apr 2022: 81 published
Quarter from 1 Jul 2022: 44 published
Quarter from 1 Oct 2022: 18 published
Quarter from 1 Jan 2023: 18 published
Quarter from 1 Apr 2023: 25 published
Quarter from 1 Jul 2023: 41 published
Quarter from 1 Oct 2023: 29 published
Quarter from 1 Jan 2024: 15 published
Quarter from 1 Apr 2024: 28 published
Quarter from 1 Jul 2024: 65 published
Quarter from 1 Oct 2024: 36 published
Quarter from 1 Jan 2025: 42 published
Quarter from 1 Apr 2025: 44 published
Quarter from 1 Jul 2025: 65 published
Quarter from 1 Oct 2025: 37 published
Quarter from 1 Jan 2026: 29 published
Quarter from 1 Apr 2026: 41 published
Quarter from 1 Jul 2026: 67 published
Quarter from 1 Oct 2026: 60 published
Revenue per quarter
Quarter ended 31 Dec 2021: $2.1B, +27% on a year earlier; public on 10 Feb 2022
Quarter ended 31 Mar 2022: $2.1B, +22% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $2.2B, +22% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $2.3B, +18% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $2.3B, +11% on a year earlier; public on 11 Feb 2023
Quarter ended 31 Mar 2023: $2.4B, +13% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $2.5B, +14% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $2.5B, +6.4% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $2.5B, +9.3% on a year earlier; public on 16 Feb 2024
Quarter ended 31 Mar 2024: $2.7B, +13% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $2.6B, +6.1% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $2.8B, +12% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $2.9B, +16% on a year earlier; public on 14 Feb 2025
Quarter ended 31 Mar 2025: $2.8B, +3.0% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $3.0B, +12% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $3.1B, +11% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $3.2B, +9.5% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $3.0B, +7.8% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $3.3B, +12% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $3.4B, +12% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $61.7M, +29% on a year earlier; public on 10 Feb 2022
Quarter ended 31 Mar 2022: $63.6M, -10% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $53.3M, +6.9% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $54.2M, +3.2% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $33.6M, -46% on a year earlier; public on 11 Feb 2023
Quarter ended 31 Mar 2023: $42.1M, -34% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $59.6M, +12% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $40.6M, -25% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $58.1M, +73% on a year earlier; public on 16 Feb 2024
Quarter ended 31 Mar 2024: $68.4M, +62% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $69.0M, +16% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $67.7M, +67% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $92.6M, +59% on a year earlier; public on 14 Feb 2025
Quarter ended 31 Mar 2025: $40.7M, -40% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $145.7M, +111% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $101.8M, +50% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $149.4M, +61% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $133.4M, +228% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $112.2M, -23% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $97.3M, -4.4% on a year earlier; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 915; public on 14 Feb 2022
31 Mar 2022 report: 1,002; public on 16 May 2022
30 Jun 2022 report: 1,029; public on 15 Aug 2022
30 Sep 2022 report: 1,018; public on 14 Nov 2022
31 Dec 2022 report: 1,117; public on 14 Feb 2023
31 Mar 2023 report: 1,121; public on 15 May 2023
30 Jun 2023 report: 1,179; public on 14 Aug 2023
30 Sep 2023 report: 1,181; public on 14 Nov 2023
31 Dec 2023 report: 1,331; public on 14 Feb 2024
31 Mar 2024 report: 1,407; public on 15 May 2024
30 Jun 2024 report: 1,467; public on 14 Aug 2024
30 Sep 2024 report: 1,448; public on 14 Nov 2024
31 Dec 2024 report: 1,468; public on 14 Feb 2025
31 Mar 2025 report: 1,533; public on 15 May 2025
30 Jun 2025 report: 1,478; public on 14 Aug 2025
30 Sep 2025 report: 1,437; public on 14 Nov 2025
31 Dec 2025 report: 1,588; public on 17 Feb 2026
31 Mar 2026 report: 1,639; public on 15 May 2026
30 Jun 2026 report: 1,717; public on 14 Aug 2026
30 Sep 2026 report: 1,772; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $630K published
Quarter from 1 Apr 2022: $520K published
Quarter from 1 Jul 2022: $520K published
Quarter from 1 Oct 2022: $710K published
Quarter from 1 Jan 2023: $370K published
Quarter from 1 Apr 2023: $670K published
Quarter from 1 Jul 2023: $630K published
Quarter from 1 Oct 2023: $890K published
Quarter from 1 Jan 2024: $920K published
Quarter from 1 Apr 2024: $1.1M published
Quarter from 1 Jul 2024: $980K published
Quarter from 1 Oct 2024: $1.0M published
Quarter from 1 Jan 2025: $970K published
Quarter from 1 Apr 2025: $1.6M published
Quarter from 1 Jul 2025: $1.1M published
Quarter from 1 Oct 2025: $1.1M published
Quarter from 1 Jan 2026: $1.1M published
Quarter from 1 Apr 2026: $1.1M published
Quarter from 1 Jul 2026: $1.2M published
Quarter from 1 Oct 2026: $1.2M published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is H-1B/E-3 applications certified at 42 (Aug 2026), 4.0× its normal month; higher than 96% of its own history.
  • Lobbying on a new issue: lobbying on a new issue Public on 20 Jul 2026.
  • Insider net buying (open market): Insiders sold a net $140.1M in the last 12 months (the 12 months before: -$47.1M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 197 published in the last 12 months, +4.8% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 4 sales, $15.4M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Nancy ThornberryDirectorSellplanned in advance (10b5-1)1,000$547.86$548KForm 4
18 Nov 2026Sangeeta N. BhatiaDirectorSellplanned in advance (10b5-1)271$547.86$148KForm 4
16 Nov 2026Charles F Wagner JrEVP, CO & FOSellplanned in advance (10b5-1)15,286$547.87$8.4MForm 4
10 Nov 2026Reshma KewalramaniCEO & PresidentSellplanned in advance (10b5-1)11,866$531.53$6.3MForm 4
7 Jul 2026Duncan McKechnieEVP, Chief Commercial OfficerSellplanned in advance (10b5-1)1,541$519.00$800KForm 4
7 Jul 2026Ourania TatsisEVP, Chief Reg. & Quality Off.Sellplanned in advance (10b5-1)1,500$524.99$787KForm 4
6 Jul 2026Joy LiuEVP and Chief Legal OfficerSellplanned in advance (10b5-1)828$502.71$416KForm 4
30 Jun 2026Carmen BozicEVP and CMOSellplanned in advance (10b5-1)596$482.50$288KForm 4

1,772 institutions reported shares at the end of Q3 2026, 94% of the shares outstanding; 143 opened a position, 102 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Capital World Investors26.0M10.2%$13.6B-148K-0.6%
BlackRock, Inc.23.8M9.39%$12.4B-306K-1.3%
Capital Research Global Investors17.8M7.03%$9.3B-1.7M-8.6%
Vanguard Capital Management LLC16.6M6.55%$8.7B+15K+0.1%
State Street Corp12.0M4.74%$6.3B+153K+1.3%
Invesco Ltd.8.3M3.27%$4.3B+238K+3.0%
Geode Capital Management, LLC6.1M2.40%$3.2B+64K+1.1%
JPMorgan Chase & Co5.7M2.24%$3.0B-826K-13%
Capital International Investors5.1M2.00%$2.6B+364K+7.8%
Vanguard Portfolio Management LLC4.9M1.95%$2.6B+66K+1.3%

Company events

All 38 company events

In 12 months: 4 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Oct 2026Director or officer change8-K
1 Sep 2026Director or officer change8-K
6 Jul 2026Signed a major agreement8-K
13 May 2026Director or officer changeSame filing: shareholder vote results8-K
29 Apr 2026Director or officer change8-K
4 Aug 2025Director or officer change8-K
10 Feb 2025Director or officer change8-K
16 Aug 2024Signed a major agreement8-K

268 open postings; careers site tracked since 20 Nov 2026. Most in Research & science 9%, Test, quality & reliability 6%, Data & analytics 6%, Sales & business development 4%.

PostedJobLocation
22 Nov 2026Associate Director, Quality Product Complaints (Hybrid)Test, quality & reliabilityBoston, MA
22 Nov 2026BSMO Business Transformation & Innovation Senior DirectorBoston, MA
22 Nov 2026Senior Manager, Strategy & Operations, Analytics & InsightsData & analyticsBoston, MA
22 Nov 2026Employee Relations and HR Governance Associate DirectorPeople & recruitingBoston, MA
22 Nov 2026Director, Modeling & SimulationBoston, MA
20 Nov 2026or earlierMedical Writing Science Senior Manager (Hybrid)Boston, MA
20 Nov 2026or earlierSenior Director - US Medical Affairs - NephrologyBoston, MA
20 Nov 2026or earlierAssociate Director Medical Writing (Hybrid)Boston, MA

Reported lobbying spend: $1.2M in Q3 2026, $1.2M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
12 Mar 2026NewAlston & Bird LLPfor Vertex Pharmaceuticals IncorporatedFY2027 Appropriations bills.Budget, Health issuesFiling
5 Feb 2026NewAlb Solutionsfor Vertex PharmaceuticalsNon-opioid pain relief and drug pipeline issues.PharmacyFiling
31 Jan 2026EndedSalt Point Strategiesfor Vertex PharmaceuticalsNon-opioid pain relief and drug pipeline issues.PharmacyFiling
12 Mar 2025NewMclarty Inbound LLCfor Vertex Pharmaceuticals IncorporatedSupporting Vertex on trade-related issues.TradeFiling
6 Feb 2025NewSalt Point Strategiesfor Vertex PharmaceuticalsNon-opioid pain relief and drug pipeline issues.PharmacyFiling
3 Feb 2025NewMarshall & Popp, LLCfor Vertex Pharmaceuticals IncorporatedIssues related to pain management.Health issues, Medicare/Medicaid, Taxation, BudgetFiling
6 Dec 2024NewCGCN Group, LLCfor Vertex Pharmaceuticals IncorporatedAccess to innovative non-opioid medicines; Alternatives to PAIN, HR 7142; Alternatives to PAIN, S 3832.Health issues, Medicare/MedicaidFiling
12 Nov 2024NewHolland & Knight LLPfor Vertex Pharmaceuticals IncorporatedTax Reform - Restoring the Orphan Drug Tax Credit.TaxationFiling

The 5 newest of 510 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Feb 2026confirmed

Confirmed across sources Filings + Financials and Lobbying

Vertex Pharmaceuticals (VRTX): lobbying on a new issue, while it spent $149.4M on capital projects in the quarter ended 31 Dec 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 27 days.

  • Lobbying: Lobbying on a new issue, became public on 21 Jan 2026
  • Financials: Quarterly capital spending jump, became public on 17 Feb 2026
2023-12-31: $58.1M2024-03-31: $68.4M2024-06-30: $69.0M2024-09-30: $67.7M2024-12-31: $92.6M2025-03-31: $40.7M2025-06-30: $145.7M2025-09-30: $101.8M2025-12-31: $149.4M
The quarter ended 31 Dec 2025 against the 8 quarters before it. this quarterearliernormal: $68.7M
See the evidence (2 changes)

Lobbying: Lobbying on a new issue became public on 21 Jan 2026

Vertex Pharmaceuticals lobbying on a new issue.

New
['VET']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4689655

Financials: Quarterly capital spending jump became public on 17 Feb 2026

Vertex Pharmaceuticals spent $149.4M on capital projects in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.

This period
$149.4M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$68.7M
Typical spread (median absolute deviation)
$17.2M
How far from its usual level
+3.2
Same quarter last year
$92.6M
History used
6,119 days
2023-12-31: $58.1M2024-03-31: $68.4M2024-06-30: $69.0M2024-09-30: $67.7M2024-12-31: $92.6M2025-03-31: $40.7M2025-06-30: $145.7M2025-09-30: $101.8M2025-12-31: $149.4M
the quarter ended 31 Dec 20258 earlier quartersnormal: $68.7M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

21 Apr 2025confirmed

Confirmed across sources Lobbying and Short interest and volume

Vertex Pharmaceuticals (VRTX): had 5.8M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 19 days.

  • Short interest and volume: Short interest spike, became public on 26 Mar 2025
  • Lobbying: Lobbying on a new issue, became public on 21 Apr 2025
2024-03-15: 4.1M2024-03-28: 4.0M2024-04-15: 4.0M2024-04-30: 3.9M2024-05-15: 3.8M2024-05-31: 4.3M2024-06-14: 4.5M2024-06-28: 4.1M2024-07-15: 4.1M2024-07-31: 5.1M2024-08-15: 4.4M2024-08-30: 4.4M2024-09-13: 4.3M2024-09-30: 4.1M2024-10-15: 4.3M2024-10-31: 4.5M2024-11-15: 4.1M2024-11-29: 3.7M2024-12-13: 3.5M2024-12-31: 4.0M2025-01-15: 4.4M2025-01-31: 4.6M2025-02-14: 5.1M2025-02-28: 5.5M2025-03-14: 5.8M
The 14 Mar 2025 report against the 24 reports before it. this reportearliernormal: 4.2M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 26 Mar 2025

Vertex Pharmaceuticals had 5.8M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year.

This period
5.8M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
4.2M
Typical spread (median absolute deviation)
224K
How far from its usual level
+3.7
Same report last year
4.1M
History used
2,632 days
2024-03-15: 4.1M2024-03-28: 4.0M2024-04-15: 4.0M2024-04-30: 3.9M2024-05-15: 3.8M2024-05-31: 4.3M2024-06-14: 4.5M2024-06-28: 4.1M2024-07-15: 4.1M2024-07-31: 5.1M2024-08-15: 4.4M2024-08-30: 4.4M2024-09-13: 4.3M2024-09-30: 4.1M2024-10-15: 4.3M2024-10-31: 4.5M2024-11-15: 4.1M2024-11-29: 3.7M2024-12-13: 3.5M2024-12-31: 4.0M2025-01-15: 4.4M2025-01-31: 4.6M2025-02-14: 5.1M2025-02-28: 5.5M2025-03-14: 5.8M
the 14 Mar 2025 report24 earlier reportsnormal: 4.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying on a new issue became public on 21 Apr 2025

Vertex Pharmaceuticals lobbying on a new issue.

New
['DEF', 'TRD']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6139847

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

15 Feb 2022confirmed

Confirmed across sources Filings + Financials and Lobbying

Vertex Pharmaceuticals (VRTX): reported $630K of lobbying spend for the quarter ended 31 Dec 2021, 1.1× the same quarter last year, while it reported revenue of $2.1B for the quarter ended 31 Dec 2021, 1.3× the same quarter last year. Two unrelated kinds of activity within 21 days.

  • Lobbying: Lobbying spend jump, became public on 20 Jan 2022
  • Financials: Quarterly revenue change, became public on 15 Feb 2022
2019-12-31: $550K2020-03-31: $410K2020-06-30: $400K2020-09-30: $400K2020-12-31: $590K2021-03-31: $430K2021-06-30: $440K2021-09-30: $530K2021-12-31: $630K
The quarter ended 31 Dec 2021 against the 8 quarters before it. this quarterearliernormal: $435K
See the evidence (2 changes)

Lobbying: Lobbying spend jump became public on 20 Jan 2022

Vertex Pharmaceuticals reported $630K of lobbying spend for the quarter ended 31 Dec 2021, 1.1× the same quarter last year.

This period
$630K (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
$435K
Typical spread (median absolute deviation)
$35K
How far from its usual level
+3.8
Same quarter last year
$590K
History used
4,202 days
2019-12-31: $550K2020-03-31: $410K2020-06-30: $400K2020-09-30: $400K2020-12-31: $590K2021-03-31: $430K2021-06-30: $440K2021-09-30: $530K2021-12-31: $630K
the quarter ended 31 Dec 20218 earlier quartersnormal: $435K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Financials: Quarterly revenue change became public on 15 Feb 2022

Vertex Pharmaceuticals reported revenue of $2.1B for the quarter ended 31 Dec 2021, 1.3× the same quarter last year.

This period
$2.1B (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
$1.6B
Typical spread (median absolute deviation)
$104.6M
How far from its usual level
+3.1
Same quarter last year
$1.6B
History used
4,658 days
2019-12-31: $1.4B2020-03-31: $1.5B2020-06-30: $1.5B2020-09-30: $1.5B2020-12-31: $1.6B2021-03-31: $1.7B2021-06-30: $1.8B2021-09-30: $2.0B2021-12-31: $2.1B
the quarter ended 31 Dec 20218 earlier quartersnormal: $1.6B

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 20 Oct 2026Filings record

    Director or officer change

  2. 1 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 1 Sep 2026Filings record

    Director or officer change

  4. 20 Jul 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['DOC']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4556012
  5. 13 May 2026Filings record

    Director or officer change

  6. 29 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 29 Apr 2026Filings record

    Director or officer change

  8. 17 Apr 2026Lobbying record

    VERTEX PHARMACEUTICALS: lobbying engagement terminated (SALT POINT STRATEGIES) (dated 31 Jan 2026)

  9. 20 Mar 2026Lobbying record

    VERTEX PHARMACEUTICALS INCORPORATED: new lobbying registration (ALSTON & BIRD LLP) (dated 12 Mar 2026)

  10. 10 Mar 2026Lobbying record

    VERTEX PHARMACEUTICALS: new lobbying registration (ALB SOLUTIONS) (dated 5 Feb 2026)

  11. 17 Feb 2026several at once

    lobbying on a new issue, while it spent $149.4M on capital projects in the quarter ended 31 Dec 2025, 1.6× the same quarter last year. Two unrelated kinds of activity within 27 days.

    See the evidence (2 changes)

    Lobbying: Lobbying on a new issue became public on 21 Jan 2026

    Vertex Pharmaceuticals lobbying on a new issue.

    New
    ['VET']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4689655

    Financials: Quarterly capital spending jump became public on 17 Feb 2026

    Vertex Pharmaceuticals spent $149.4M on capital projects in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.

    This period
    $149.4M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $68.7M
    Typical spread (median absolute deviation)
    $17.2M
    How far from its usual level
    +3.2
    Same quarter last year
    $92.6M
    History used
    6,119 days
    2023-12-31: $58.1M2024-03-31: $68.4M2024-06-30: $69.0M2024-09-30: $67.7M2024-12-31: $92.6M2025-03-31: $40.7M2025-06-30: $145.7M2025-09-30: $101.8M2025-12-31: $149.4M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $68.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  12. 17 Feb 2026Financials change

    spent $149.4M on capital projects in the quarter ended 31 Dec 2025, 1.6× the same quarter last year.

    Same quarter last year: $92.6M; its normal quarter is $68.7M.

    See the evidence
    This period
    $149.4M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $68.7M
    Typical spread (median absolute deviation)
    $17.2M
    How far from its usual level
    +3.2
    Same quarter last year
    $92.6M
    History used
    6,119 days
    2023-12-31: $58.1M2024-03-31: $68.4M2024-06-30: $69.0M2024-09-30: $67.7M2024-12-31: $92.6M2025-03-31: $40.7M2025-06-30: $145.7M2025-09-30: $101.8M2025-12-31: $149.4M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $68.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  13. 12 Feb 2026Institutional holdings record

    Winslow Capital Management, LLC opened a $405.0M position (2025Q4 13F)

  14. 21 Jan 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['VET']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4689655
  15. 8 Aug 2025Insiders record

    Kewalramani Reshma (CEO & President) bought 10,000 shares of VRTX ($3.9M) (dated 7 Aug 2025)

  16. 8 Aug 2025Insiders record

    SACHS BRUCE I (director) bought 5,000 shares of VRTX ($1.9M) (dated 7 Aug 2025)

  17. 7 Aug 2025Financials change

    spent $145.7M on capital projects in the quarter ended 30 Jun 2025, 2.1× the same quarter last year.

    Same quarter last year: $69.0M; its normal quarter is $63.6M.

    See the evidence
    This period
    $145.7M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $63.6M
    Typical spread (median absolute deviation)
    $5.5M
    How far from its usual level
    +10.2
    Same quarter last year
    $69.0M
    History used
    3,378 days
    2023-06-30: $59.6M2023-09-30: $40.6M2023-12-31: $58.1M2024-03-31: $68.4M2024-06-30: $69.0M2024-09-30: $67.7M2024-12-31: $92.6M2025-03-31: $40.7M2025-06-30: $145.7M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $63.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  18. 4 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 4 Aug 2025Filings record

    Director or officer change

  20. 21 Apr 2025several at once

    had 5.8M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 19 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 26 Mar 2025

    Vertex Pharmaceuticals had 5.8M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year.

    This period
    5.8M (the 14 Mar 2025 report)
    Normal report (median of 24 earlier)
    4.2M
    Typical spread (median absolute deviation)
    224K
    How far from its usual level
    +3.7
    Same report last year
    4.1M
    History used
    2,632 days
    2024-03-15: 4.1M2024-03-28: 4.0M2024-04-15: 4.0M2024-04-30: 3.9M2024-05-15: 3.8M2024-05-31: 4.3M2024-06-14: 4.5M2024-06-28: 4.1M2024-07-15: 4.1M2024-07-31: 5.1M2024-08-15: 4.4M2024-08-30: 4.4M2024-09-13: 4.3M2024-09-30: 4.1M2024-10-15: 4.3M2024-10-31: 4.5M2024-11-15: 4.1M2024-11-29: 3.7M2024-12-13: 3.5M2024-12-31: 4.0M2025-01-15: 4.4M2025-01-31: 4.6M2025-02-14: 5.1M2025-02-28: 5.5M2025-03-14: 5.8M
    the 14 Mar 2025 report24 earlier reportsnormal: 4.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Lobbying: Lobbying on a new issue became public on 21 Apr 2025

    Vertex Pharmaceuticals lobbying on a new issue.

    New
    ['DEF', 'TRD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6139847

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  21. 21 Apr 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['DEF', 'TRD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6139847
  22. 3 Apr 2025Lobbying record

    VERTEX PHARMACEUTICALS INCORPORATED: new lobbying registration (MCLARTY INBOUND LLC) (dated 12 Mar 2025)

  23. 26 Mar 2025Short interest and volume change

    had 5.8M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year.

    Same report last year: 4.1M; its normal report is 4.2M.

    See the evidence
    This period
    5.8M (the 14 Mar 2025 report)
    Normal report (median of 24 earlier)
    4.2M
    Typical spread (median absolute deviation)
    224K
    How far from its usual level
    +3.7
    Same report last year
    4.1M
    History used
    2,632 days
    2024-03-15: 4.1M2024-03-28: 4.0M2024-04-15: 4.0M2024-04-30: 3.9M2024-05-15: 3.8M2024-05-31: 4.3M2024-06-14: 4.5M2024-06-28: 4.1M2024-07-15: 4.1M2024-07-31: 5.1M2024-08-15: 4.4M2024-08-30: 4.4M2024-09-13: 4.3M2024-09-30: 4.1M2024-10-15: 4.3M2024-10-31: 4.5M2024-11-15: 4.1M2024-11-29: 3.7M2024-12-13: 3.5M2024-12-31: 4.0M2025-01-15: 4.4M2025-01-31: 4.6M2025-02-14: 5.1M2025-02-28: 5.5M2025-03-14: 5.8M
    the 14 Mar 2025 report24 earlier reportsnormal: 4.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 24 Mar 2025Lobbying record

    VERTEX PHARMACEUTICALS INCORPORATED: new lobbying registration (MARSHALL & POPP, LLC) (dated 3 Feb 2025)

  25. 24 Feb 2025Lobbying record

    VERTEX PHARMACEUTICALS: new lobbying registration (SALT POINT STRATEGIES) (dated 6 Feb 2025)

  26. 11 Feb 2025Institutional holdings record

    WCM INVESTMENT MANAGEMENT, LLC opened a $436.0M position (2024Q4 13F)

  27. 10 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 10 Feb 2025Institutional holdings record

    PARNASSUS INVESTMENTS, LLC opened a $731.0M position (2024Q4 13F)

  29. 10 Feb 2025Filings record

    Director or officer change

  30. 4 Feb 2025Attention change

    drew 9,043 Wikipedia page views in the week of 27 Jan 2025, 2.8× the same week last year.

    Same week last year: 3,280; its normal week is 1,520.

    See the evidence
    This period
    9,043 (the week of 27 Jan 2025)
    Normal week (median of 26 earlier)
    1,520
    Typical spread (median absolute deviation)
    98.5
    How far from its usual level
    +37.6
    Same week last year
    3,280
    History used
    2,224 days
    2024-07-29: 1,3432024-08-05: 1,2712024-08-12: 1,3912024-08-19: 1,5212024-08-26: 1,5152024-09-02: 1,4162024-09-09: 1,5562024-09-16: 1,5182024-09-23: 1,6132024-09-30: 1,5372024-10-07: 1,4962024-10-14: 1,5692024-10-21: 1,5252024-10-28: 1,4632024-11-04: 1,7042024-11-11: 1,7142024-11-18: 1,7812024-11-25: 1,4732024-12-02: 1,6382024-12-09: 1,4902024-12-16: 1,6512024-12-23: 1,2932024-12-30: 1,1142025-01-06: 1,8742025-01-13: 2,0222025-01-20: 1,4582025-01-27: 9,043
    the week of 27 Jan 202526 earlier weeksnormal: 1,520

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  31. 9 Jan 2025Lobbying record

    VERTEX PHARMACEUTICALS INCORPORATED: new lobbying registration (HOLLAND & KNIGHT LLP) (dated 12 Nov 2024)

  32. 19 Dec 2024Lobbying record

    VERTEX PHARMACEUTICALS INCORPORATED: new lobbying registration (CGCN GROUP, LLC) (dated 6 Dec 2024)

  33. 10 Jul 2024Institutional holdings record

    AMF Tjanstepension AB opened a $258.0M position (2024Q2 13F)

  34. 22 Apr 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['HOM']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6541714
  35. 28 Feb 2024Short interest and volume change

    had 4.1M shares sold short in the 15 Feb 2024 report, 1.5× the same report last year.

    Same report last year: 2.8M; its normal report is 2.9M.

    See the evidence
    This period
    4.1M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    2.9M
    Typical spread (median absolute deviation)
    196K
    How far from its usual level
    +4.4
    Same report last year
    2.8M
    History used
    2,239 days
    2023-02-15: 2.8M2023-02-28: 2.7M2023-03-15: 2.9M2023-03-31: 3.5M2023-04-14: 3.4M2023-04-28: 3.2M2023-05-15: 3.2M2023-05-31: 3.1M2023-06-15: 2.7M2023-06-30: 2.7M2023-07-14: 2.5M2023-07-31: 2.9M2023-08-15: 2.7M2023-08-31: 2.9M2023-09-15: 2.9M2023-09-29: 2.9M2023-10-13: 2.9M2023-10-31: 2.6M2023-11-15: 2.5M2023-11-30: 2.7M2023-12-15: 3.6M2023-12-29: 3.3M2024-01-12: 3.4M2024-01-31: 3.3M2024-02-15: 4.1M
    the 15 Feb 2024 report24 earlier reportsnormal: 2.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 5 Dec 2023Filings record

    Director or officer change

  37. 5 Oct 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 5 Oct 2023Filings record

    Director or officer change

  39. 18 Aug 2023Lobbying record

    VERTEX PHARMACEUTICALS INCORPORATED: new lobbying registration (AVENUE SOLUTIONS) (dated 1 Jun 2023)

  40. 20 Jul 2023Lobbying record

    VERTEX PHARMACEUTICALS INCORPORATED: lobbying engagement terminated (CAPITOL COUNSEL LLC) (dated 30 Jun 2023)

Showing the newest 40 of 90 entries; narrow the window or the kind of data to see older ones.

Not listed: 849 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000875320
Ticker
VRTX
Domain
vrtx.com
Employer name
Vertex Pharmaceuticals (Clinical) LLC, Vertex Pharmaceuticals Incorporated (2 unverified)
Fein
41-4581545 (1 unverified)
Hq location
MA|BOSTON|02210 (1 unverified)
Lobbying client
tiber creek group on behalf of vertex pharmaceuticals, vertex pharmaceuticals
Name
a10k_2025-exhibit211.htm, AIS Operating Co., Inc., a Delaware corporation (7), Alpine Immune Sciences Australia Pty Ltd, an Australian Company (7), Alpine Immune Sciences, Inc., a Delaware corporation and 46 more
Uei
Y4NLRU471XL7
Wikidata
Q2744099
Wikipedia
Vertex Pharmaceuticals
  • DOL H-1B labor condition applications and PERM certifications1475 data points1 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)24 records, 225 data points14 Feb 2008 to 30 Sep 2026
  • SEC Form 13F institutional holdings8 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)144 records11 Jan 2016 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1187 data points31 Dec 2007 to 31 Oct 2026
  • SEC Form 4 insider transactions733 records, 1532 data points4 Jan 2016 to 18 Nov 2026
  • FINRA short interest (twice monthly)627 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards9 data points6 May 2009 to 2 Feb 2010
  • Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026